Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Seabelife SAS to develop next-gen dry AMD drug
French drug developer SeaBeLife SAS has bagged a €1.5m fund within the i-Nov 2024 innovation competition, which is part of the French government’s...
New law to speed up clinical trials
The draft Medical Research Act (Medizinforschungsgesetz) presented by Health Minister Karl Lauterbach in Berlin before Easter is the centrepiece of...
AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases
The 2021 spin-out from the Queen’s University Belfast announced it will close a seed financing round this year.vAMPLY is speeding up the discovery of...